<SEC-DOCUMENT>0001104659-15-040686.txt : 20150526
<SEC-HEADER>0001104659-15-040686.hdr.sgml : 20150525
<ACCEPTANCE-DATETIME>20150526141450
ACCESSION NUMBER:		0001104659-15-040686
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150526
FILED AS OF DATE:		20150526
DATE AS OF CHANGE:		20150526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		15888918

	BUSINESS ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA
		BUSINESS PHONE:		31-20-5667394

	MAIL ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a15-12749_16k.htm
<DESCRIPTION>6-K
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;6-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Report of Foreign Private Issuer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Rule&nbsp;13a-16 or 15d-16 of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">May&nbsp;26, 2015</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">uniQure N.V.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">J&#246;rn Aldag, Chief Executive Officer<br> Meibergdreef 61<br> Amsterdam 1105 BA, the Netherlands; Tel: +31 20 566 7394</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address,&nbsp;Including ZIP Code, and Telephone Number,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Including Area Code, of Registrant&#146;s Principal Executive Offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;20-F&#160; &#160;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1): </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7): </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107541\15-12749-1\task7428484\12749-1-ba.htm',USER='107541',CD='May 26 23:15 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished as Exhibit&nbsp;99.1 to this Report on Form&nbsp;6-K is a press release of uniQure N.V. dated May&nbsp;26, 2015, announcing the closing of the Company&#146;s collaboration and license agreement with Bristol-Myers Squibb Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_220645_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107541\15-12749-1\task7428484\12749-1-ba.htm',USER='107541',CD='May 26 23:15 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNIQURE N.V.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;26, 2015</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:   </font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/S/   J&#214;RN ALDAG</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J&#246;rn   Aldag</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_220655_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107541\15-12749-1\task7428484\12749-1-ba.htm',USER='107541',CD='May 26 23:15 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX TO EXHIBITS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:87.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   release of uniQure N.V. dated May&nbsp;26, 2015, announcing the closing of   the Company&#146;s collaboration and license agreement with Bristol-Myers Squibb   Company.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_220703_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\107541\15-12749-1\task7428484\12749-1-ba.htm',USER='107541',CD='May 26 23:15 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a15-12749_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="242" height="68" src="g127491mm01i001.jpg" alt="GRAPHIC"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Announces Closing of Strategic Collaboration with Bristol-Myers<br> Squibb to Develop Gene Therapies for Cardiovascular Disease</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-Closing Triggers $50 Million Payment to uniQure-</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amsterdam, the Netherlands, May&nbsp;26, 2015</font></b><font size="2" style="font-size:10.0pt;"> &#151; uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of its strategic collaboration with Bristol-Myers Squibb to develop gene therapies for cardiovascular disease.&#160; The transaction was previously announced on April&nbsp;6, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;This collaboration brings together our innovative and validated gene therapy platform and Bristol-Myers Squibb&#146;s expertise in discovering and developing treatments for cardiovascular diseases in an effort to advance the promise of gene therapy for the millions of patients that suffer from heart disease,&#148; said Joern Aldag, Chief Executive Officer of uniQure. &#147;The partnership enables us to significantly accelerate and expand our cardiovascular product pipeline and complements the further development of our internal product candidates targeting liver diseases, such as hemophilia, and CNS disorders, including lysosomal storage diseases.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the Collaboration Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The collaboration agreement provides </font><font size="2" style="font-size:10.0pt;">Bristol-Myers Squibb with exclusive access to uniQure&#146;s gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQure&#146;s proprietary gene therapy program for congestive heart failure that is intended to restore the heart&#146;s ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the agreement, </font><font size="2" style="font-size:10.0pt;">Bristol-Myers Squibb will make near-term payments of approximately $100 million, including an initial upfront payment of $50 million upon closing of the transaction, a $15 million payment upon selection of three collaboration targets, in addition to S100A1, to be made within three months of closing, and an initial equity investment in uniQure representing 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or approximately $37 million in total. The initial equity investment is expected to close on June&nbsp;12, 2015.&#160; Bristol-Myers-Squibb will acquire an additional 5.0% ownership before December&nbsp;31, 2015, at a 10% premium, and has been granted two warrants, each to acquire up to an additional 5% equity interest, at a premium, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254 million for the lead S1A001 therapeutic and up to $217 million for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales based milestone payments and tiered single to double-digit royalties on product sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\brama\15-12749-1\task7428327\12749-1-mm-01.htm',USER='105435',CD='May 26 22:07 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;look forward to&#148;, &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of gene therapies for cardiovascular disease, the success of our collaboration with Bristol-Myers Squibb, the election by Bristol-Myers Squibb to extend the range of target indications covered by our collaboration, and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators&#146; clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in 2014 Annual Report on Form&nbsp;20-F filed with the Securities and Exchange Commission on April&nbsp;7, 2015. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aicha Diba</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct&nbsp;: +31 20 240 6100</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +31 20 240 6000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a.diba@uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media inquiries:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gretchen Schweitzer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MacDougall Biomedical Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +49 172 861 8540</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +49 89 2424 3494 or +1 781 235 3060</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gschweitzer@macbiocom.com</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\brama\15-12749-1\task7428327\12749-1-mm-01.htm',USER='105435',CD='May 26 22:07 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g127491mm01i001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g127491mm01i001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!$`/(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`***0YP<=>U`%>74;*"80RW4*2'HC.`:L5Y3=B9;N8
M7.?.WG?NZYS7HWA\3KH=J+G/F;/XNN,\?IBO,P>.EB*DH.-K'J8S`1P].,U*
M]_ZT-&D)"C)(`]369KNM1Z/:A@`\\G$:'^9]JX&\U&\U"7?<SO(2>%SP/H*K
M%YA3P[Y;79.$RZIB%SWM$]/66-SA'5C['-/KR8I-;D,4DB/8X*UT>@^*9X)D
MM=0D,D+'`E;[R'W/<5ST,VA.7+4CRG17RB<(<U.7,=M124M>R>*%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!7.ZSXI?2M1:T6T64!0VXR8Z_A715Y_X
MP_Y#[_\`7-*\_,:TZ-'F@[.YZ.6T:=:MRU%=6.PT74SJVGBZ:(1$L5VAL]*;
MKNK-H]DMPL(E+2!-I;'8_P"%5/!W_(!7_KJW\ZB\;?\`(&C_`.NX_D:)5IK!
M>UO[UK@J-/Z][*WNWM8?H?B5]8OFMFM5B"QE]P?/<>WO6CJ^H'2]-DNUC$A0
M@;2<9R<5R7@K_D-2?]<#_,5T7BS_`)%Z?ZK_`.A"L</B*L\'*I)^\KFV(P]*
M&-C2BO==C-M/&R2S[;FU$,6TDNKECP.`!CO4,WCF3S/W%BNS_;?D_E7.6%G)
MJ%]%:1D!I6QD]AW-=7/X(MOLI^SW,OG@<%\;6/TQQ7!1KX^O!N#V]/N.^M0R
M_#S2J+?U^\NZ-XGMM4E%NZ&"<_=4G(;Z&MRO)D>2WF6125DB;(]B#7JT3^9"
MDF,;E!KT<MQ<\1%QGNCSLRP<,/)2I[,Y&_\`%,46HRH^DP2O#(4$C,,\'Z5U
M5G.;JRAN"NTRQA]N<XR,UYKJW_(7O?\`KN_\Z]%TC_D#V?\`UP3^0K++\14J
M5IQF]%Z=S7,</3I4:<H+5^O8XKQ=<--KTB$Y6%%0#TXR?YUK^"].A-J]_(@:
M4N40D?=`]*P/$9SX@O,_WQ_(5UO@\8\/Q^[O_.N7")5,?-RZ7_,Z\6W3R^"C
MUM^1K7-K#>0-!<1K)&PP017E]Y;FUO)[8G/E2,F?7!KU:O,]=_Y#M[_UU-;9
MS!<D9];F&2SESRATM<[S0;AKG0[25SEC&`3]./Z5EZOXK?3-2ELQ9K((P/F,
MF,Y`/I5SPI_R+MM_P+_T(UR?BO\`Y&*Y^B?^@BM<5B*E/!TYP=F[?D987#TJ
MN,J0FKI7_,[;1]1.J:<EVT0B+DC:#G&#BH->UEM&MXI5@$WF/MP6VXXSZ5%X
M2_Y%Z'_>?_T(U2\<_P#(/M?^NW_LIK>=:HL%[5/WK)F%.C3>.]DU[MWH6M!\
M1OK-W)`UJ(=B;\A\YYQZ5<UO5&TBP^U+$)3O"[2V.M<SX'_Y"EQ_UP_]F%;'
MC/\`Y`7_`&V7^M94<15E@G5;][4UK8>E''1I)>[IH5+3QM')(_VJV\E%0D%7
MW%CV`&*@D\=2^9^ZL4"?[3G-<_I>GOJFH1VB-MW<LW]T#J:ZFX\#VQB46UU*
MD@(R9,$$=^E<-&MF%>G>#V]#NK4<OP]3EJ+?UT-/1=>AUB*0B)H7B^^#ROX&
ML_4/&=M;RF*SA-P5X+EMJ_AZU%XB\K0]!BTZR&SSVPS=V`ZD^YXK%\.Z(NL7
M,GFLR00@;MO5B>@KHK8K$J4</!WGU9A1PN%<98F:M#HOZ\S3A\=2;_W]BI7_
M`&'Y_6NFT[4[75+?S[5]P'#*>"I]"*P-7\(VD=C)/8[TEB4MM9MP8#KU[UA>
M&[]K'682&Q',1&X[$'I^1I0Q.)PU94\0[I]0GA<-B:,JF'5FNAZ/1117NG@A
M1110`5Y_XP_Y#[_]<TKT"N$\:6[QZPDQ'R2Q#!]QU_I7E9LF\/\`-'K90TL3
M\F;O@[_D`K_UU;^=1^-O^0-'_P!=Q_(UC>'/$D>E0O:W,;M$6W*R<E3W&*C\
M1^(%UCRX8(V2",[LOU8UR2Q='ZCR7UM:QUQP=;Z_[2WNWO<D\%?\AJ3_`*X'
M^8KHO%G_`"+T_P!5_P#0A7.^"O\`D-2?]<#_`#%=%XL_Y%Z?ZK_Z$*O"?\B^
M?S_(C%_\C&'_`&Z<GX6_Y&*V_P"!?^@FO1:\Z\+?\C%;?\"_]!->BUKD_P#`
M?K^B,<Y_CKT_5GD]U_Q\S_\`71OYFO4[7_CTA_ZYK_*O++K_`(^9_P#KHW\S
M7J=K_P`>D/\`US7^5891\=3Y?J=.<?!3^?Z'F>K?\A>]_P"N[_SKT72/^0/9
M_P#7!/Y"O.M6_P"0O>_]=W_G7HND?\@>S_ZX)_(4LK_CU/ZZAFO^[T_ZZ'">
M)EV^(;L8ZE3_`..BNI\&N&T%1G[LK#^O]:RO&FFNMPFHHI,;*$D(_A(Z&LS0
M]>ET:1U\OS8)#EDS@@^HK&$UA<=)U-G?\=3:=-XO`15/=6_#0[*\\06%EJ$=
ME+)\[_>8=(_3-<+K3B36KQU((,S8([U)K=Y8:A=?:;."6%WYE#8P3ZC'>L^-
M/,D6,,JEB!EC@#/K6&-Q<J[Y-&D]+&^!P<:"4]4VM;GH?A=2OAVUSW#'_P`>
M-<EXK_Y&*Y^B?^@BN]LK=+2RAMT.5B0*#Z^]<1XQ@:+7#*1\LT:E3].#_*O2
MS&FXX.$>UOR/-RZHIXV<N]_SN=)X2_Y%Z'_>?_T(U2\<_P#(/M?^NW_LIK-\
M/>)HM+M3:74;M&&+(Z<D9Z@BJ_B+7EUAXXX8V2"(DC=U8^M95,71>!4$];)6
M-:>$K+'NHU[MV[EKP/\`\A2X_P"N'_LPK8\9_P#("_[;+_6L?P/_`,A2X_ZX
M?^S"MCQG_P`@+_MLO]:O#_\`(ME\R,1_R,H_(P/!O_(>'_7)OZ5WU<#X-_Y#
MP_ZY-_2N^KHRG_=_FSGS?_>?DCC?'6?M%GZ;'_F*P]/CU5T<Z<+G:"-_DL1S
M[XKJ_&=B]QIL=S&N3;MEL?W3U/\`*N<\/ZV=&N7+H7@E`#A>HQT(KS<9"*QO
M[QM)]?D>G@YR>!7LTFUT?K_D2&V\3,""NH$'J"Y_QJ&VT354NH6-A.`LBDG;
MTYKJ9?&>EI$6C\Z1\<($Q^IINA>*5U*X:VND6&5B3%CHP]/K_.M?JV$E4C'V
MK;,OK.+C3E+V22.AHHHKZ(^;"BBB@`JGJ6F6VJVIM[E21G*L.JGU%7**F48S
M3C)71492A)2B[-'&R>!I_,/EWT93L60@U9/@B$67EK=$W!8$RLO`'H!FNIHK
MB66X97]W\SN>98IV][\$8&A^&GT>^:Y:Z$H:,IM"8[CW]JT=7T\ZIILEHL@C
M+D'<1G&#FKU%;PPU*%-THKW6<\\35G4563]Y?H<UI/A-]-U**[-XL@CS\HCQ
MG(QZUTM%%51H4Z$>6FK(5>O4KRYJCNSD)?`\DDKO_:"C>Q./*Z9/UKK(D\J%
M(\YVJ!GUQ3Z*FCAJ5!MTU:Y5;%5:Z2J.]CE+SP7)=7D]P+Y5$LC/CRLXR?K7
M26<!M;*&W+;C$@3=C&<#%3T44L+2HR<H*S85L55K149NZ0R2-)HVCD0.C##*
MPR"*YJ^\$P2N7LK@P`_\LW&X#Z'K7444ZV'I5U:HKDT<35H.]-V.,C\#3EQY
MM]&%[[4)-2:CX*VQ1'3I"SYVR"4]?]K_`.M77T5S?V;AN5KE.K^T\5S*7,5=
M.L_[/L(K7S7E\L8W,>O_`-:F:II5MJUMY-P#P<HZ]5/M5VBNQTX.'(UH<2JS
M4_:)Z[G&/X&N/,^2^C*>K(<U:?P1#]C$<=T?/W`M*RY&/0#-=317&LMPJO[O
MYG8\RQ3M[WX(P=!\./HUW).UT)MZ;,!,8YSZU=UO2VU>P^RK*(CO#;BN>E:-
M%=$<-2C2=)+W3GEB:LJJJM^\CGM%\,/I.H?:FNUE&PKM"8Z_C70T455&C"C'
ME@K(FM7J5I<U1W8A`92K`$$8(/>N9O\`P5;S2&2SG-ODY\MAN7\.XKIZ*5;#
MTJRM45QT<15H.]-V.+7P-<EOGO8@/4(2:W])\/6>D?/&#+.1@ROU'T':M6BL
MJ6!P]*7-&.IM6Q^(K1Y92T"BBBNPX@HHHH`****`"BBB@`HHHH`****`"BBB
L@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
